PCI Pharma Services, a global biopharmaceutical outsourcing services provider, has acquired San Diego-based Sherpa Clinical Packaging, which will expand PCI’s US operations to the West Coast.
The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position in the outsourcing clinical trial support services space.
Founded in 2010, Sherpa’s core services include primary and secondary packaging and labelling for phase I-IV studies, distribution, storage and returns. Sherpa’s facilities employ the most current cold chain technologies that include handling products requiring labelling and kitting in frozen and refrigerated conditions.
Bill Mitchell, executive vice chairman of PCI, said: “The team at Sherpa have done an excellent job of building a customer-centric organisation with a strong service reputation. Their dedication parallels our own commitment to provide the industry leading customer experience, which makes them a natural fit for PCI.”
Salim Haffar, PCI’s newly appointed CEO, commented: “I am delighted to join PCI during this period of rapid expansion and strategic investment, which will allow PCI to better partner with our biopharma customers. The acquisition of Sherpa is the next logical step in our clinical services expansion strategy, further enhancing our development-stage capabilities and geographic presence.”
According to PCI, the company has been rapidly growing its capabilities and global presence to offer differentiated solutions for its clients. PCI’s global molecule-to-market services span contract development and manufacturing, including specialisation in highly complex and potent drugs, clinical supply services and commercial packaging services.